Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Gynecologic Oncology

Volumn 139, Issue 1, 2015, Pages 112-117

  Schwab, Carlton L ^a   English, Diana P ^a   Black, Jonathan ^a   Bellone, Stefania ^a   Lopez, Salvatore ^b   Cocco, Emiliano ^a   Bonazzoli, Elena ^a   Bussi, Beatrice ^a   Predolini, Federica ^a   Ferrari, Francesca ^a   Ratner, Elena ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Rutherford, Thomas ^a   Schwartz, Peter E ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Carcinosarcoma; ErbB2; HER2 neu; Targeted therapy; TKI

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERATINIB; ERBB2 PROTEIN, HUMAN; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOSARCOMA; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; G1 PHASE CELL CYCLE CHECKPOINT; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOSARCOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE AMPLIFICATION; HUMANS; MICE; MICE, SCID; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943348015     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.08.002     Document Type: Article

References (22)

1. R. Arend, J.A. Doneza, and J.D. Wright Uterine carcinosarcoma Curr. Opin. Oncol. 23 2011 531 536
2. F. Guzzo, S. Bellone, N. Buza, P. Hui, L. Carrara, J. Varughese, and et al. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas Int. J. Gynecol. Pathol. 31 2012 211 221
3. J. Gonzalez Bosquet, S.A. Terstriep, W.A. Cliby, M. Brown-Jones, J.S. Kaur, K.C. Podratz, and et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas Gynecol. Oncol. 116 2010 419 423
4. J.A. Rauh-Hain, E.J. Diver, J.T. Clemmer, L.S. Bradford, R.M. Clark, W.B. Growdon, and et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis Gynecol. Oncol. 131 2013 46 51
5. I.A. Voutsadakis Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Mullerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities Clin. Transl. Oncol. 14 2012 243 253
6. M.A. Castilla, G. Moreno-Bueno, L. Romero-Perez, K. Van De Vijver, M. Biscuola, M.A. Lopez-Garcia, and et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma J. Pathol. 223 2011 72 80
7. M. Zeisberg, and E.G. Neilson Biomarkers for epithelial-mesenchymal transitions J. Clin. Invest. 119 2009 1429 1437
8. C. Mirantes, I. Espinosa, I. Ferrer, X. Dolcet, J. Prat, and X. Matias-Guiu Epithelial-to-mesenchymal transition and stem cells in endometrial cancer Hum. Pathol. 44 2013 1973 1981
9. C.L. Arteaga, and J.A. Engelman ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics Cancer Cell 25 2014 282 303
10. C.L. Schwab, D.P. English, D.M. Roque, S. Bellone, S. Lopez, E. Cocco, and et al. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo Gynecol. Oncol. 135 2014 142 148
11. C.A. Livasy, F.C. Reading, D.T. Moore, J.F. Boggess, and R.A. Lininger EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma Gynecol. Oncol. 100 2006 101 106
12. K. El-Sahwi, S. Bellone, E. Cocco, M. Cargnelutti, F. Casagrande, M. Bellone, and et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma Br. J. Cancer 102 2010 134 143
13. A.C. Wolff, M.E. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J. Clin. Oncol. 25 2007 118 145
14. K.K. Wong, P.M. Fracasso, R.M. Bukowski, T.J. Lynch, P.N. Munster, G.I. Shapiro, and et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors Clin. Cancer Res. 15 2009 2552 2558
15. S.K. Rabindran, C.M. Discafani, E.C. Rosfjord, M. Baxter, M.B. Floyd, J. Golas, and et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res. 64 2004 3958 3965
16. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N. Engl. J. Med. 357 2007 39 51
17. H.R. Tsou, E.G. Overbeek-Klumpers, W.A. Hallett, M.F. Reich, M.B. Floyd, B.D. Johnson, and et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J. Med. Chem. 48 2005 1107 1131
18. Y. Ito, M. Suenaga, K. Hatake, S. Takahashi, M. Yokoyama, Y. Onozawa, and et al. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study Jpn. J. Clin. Oncol. 42 2012 278 286
19. A. Awada, L. Dirix, L. Manso Sanchez, B. Xu, T. Luu, V. Dieras, and et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy Ann. Oncol. 24 2013 109 116
20. R.C. Jankowitz, J. Abraham, A.R. Tan, S.A. Limentani, M.B. Tierno, L.M. Adamson, and et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2positive breast cancer: an NSABP Foundation Research Program phase I study Cancer Chemother. Pharmacol. 72 2013 1205 1212
21. H.J. Burstein, Y. Sun, L.Y. Dirix, Z. Jiang, R. Paridaens, A.R. Tan, and et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer J. Clin. Oncol. 28 2010 1301 1307
22. Neratinib graduates to I-SPY 3 Cancer Discov. 4 2014 624